ARMP — Armata Pharmaceuticals, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 921114 ·
Last close
$3.86
Market Cap
$143.52M
52W High
$16.34
52W Low
$3.09
ADV30
283,815
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -8,785,000 | -115,346,000 | 69,800,000 | 4,754,000 | 381,386,000 |
| Dec 2025 | 0 | — | -8,411,000 | -124,298,000 | 76,882,000 | 8,688,000 | 295,478,000 |
| Sep 2025 | 0 | — | -7,776,000 | -26,675,000 | 89,516,000 | 14,756,000 | 185,104,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,965,000
Investing CF
$-506,000
Financing CF
$16,267,000
CapEx
$-506,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.55
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-616,880,000
Inventory
—
Receivables
$47,000
ST Investments
—
EBIT TTM
$-264,067,000
Pretax Income TTM
$-282,614,000
Interest Exp TTM
$18,547,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,543,000
EBITDA
$-33,448,000
Free Cash Flow
$-27,409,624
Enterprise Value
$490,040,032
Total Cash
$23,952,000
Total Debt
$313,952,992
Shares Out
37,181,979
Trailing EPS
$-5.29
Book Value
$-6.22
ROE
—
ROA
-25.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -31,222,000 | -173,799,000 | 76,882,000 | 295,478,000 | -218,596,000 | -25,763,000 |
| Dec 2024 | 0 | -42,436,000 | -18,916,000 | 86,437,000 | 134,456,000 | -48,019,000 | -37,551,000 |
| Dec 2023 | 0 | -40,890,000 | -69,045,000 | 98,363,000 | 130,428,000 | -32,065,000 | -47,423,000 |
| Dec 2022 | 0 | -36,946,000 | -36,917,000 | 95,834,000 | 59,754,000 | 36,080,000 | -32,481,000 |
TTM Snapshot
Revenues TTM
$5,202,000
NetIncome TTM
$-282,614,000
OpCashFlow TTM
—
Assets (Latest)
$69,800,000
Forward EPS
$-1.57
Max Pain — expiry 2026-10-16
max pain strike: $7.50 · spot: $3.76 · call oi: 1,007 · put oi: 58
Expected Move to 2026-10-16:
±$1.48
(39.36%) —
implied range
$2.28 –
$5.24
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVXL | ANAVEX LIFE SCIENCES CORP. | $142.75M | $1.54 | — |
| MOLN | MOLECULAR PARTNERS AG | $145.94M | $3.81 | — |
| VYGR | Voyager Therapeutics, Inc. | $146.03M | $2.37 | — |
| OTLK | Outlook Therapeutics, Inc. | $137.30M | $0.56 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $151.87M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
2026-10-07 11:00 · Yahoo
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
2026-09-23 11:00 · Yahoo
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
2026-09-21 11:00 · Yahoo
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
2026-09-14 13:34 · Yahoo
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
2026-09-14 11:00 · Yahoo
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 11:00 · Yahoo
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
2026-09-03 11:00 · Yahoo
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
2026-07-21 11:05 · Yahoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
2026-07-20 11:00 · Yahoo
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
2026-07-13 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.